NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
© 2023. The Author(s)..
Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have shown that decision-making based on comprehensive molecular characterization adds significant clinical value. However, the complexity and heterogeneity of the resulting data are major challenges for disciplines involved in interpretation and recommendations for individualized care, and limited information exists on how to approach multilayered tumor profiles in clinical routine. We report our experience with the practical use of data from whole-genome or exome and RNA sequencing and DNA methylation profiling within the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program of the National Center for Tumor Diseases (NCT) Heidelberg and Dresden and the German Cancer Research Center (DKFZ). We cover all relevant steps of an end-to-end precision oncology workflow, from sample collection, molecular analysis, and variant prioritization to assigning treatment recommendations and discussion in the molecular tumor board. To provide insight into our approach to multidimensional tumor profiles and guidance on interpreting their biological impact and diagnostic and therapeutic implications, we present case studies from the NCT/DKFZ molecular tumor board that illustrate our daily practice. This manual is intended to be useful for physicians, biologists, and bioinformaticians involved in the clinical interpretation of genome-wide molecular information.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
NPJ precision oncology - 7(2023), 1 vom: 26. Okt., Seite 109 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 29.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41698-023-00458-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363768297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363768297 | ||
| 003 | DE-627 | ||
| 005 | 20231226094040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41698-023-00458-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363768297 | ||
| 035 | |a (NLM)37884744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mock, Andreas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have shown that decision-making based on comprehensive molecular characterization adds significant clinical value. However, the complexity and heterogeneity of the resulting data are major challenges for disciplines involved in interpretation and recommendations for individualized care, and limited information exists on how to approach multilayered tumor profiles in clinical routine. We report our experience with the practical use of data from whole-genome or exome and RNA sequencing and DNA methylation profiling within the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program of the National Center for Tumor Diseases (NCT) Heidelberg and Dresden and the German Cancer Research Center (DKFZ). We cover all relevant steps of an end-to-end precision oncology workflow, from sample collection, molecular analysis, and variant prioritization to assigning treatment recommendations and discussion in the molecular tumor board. To provide insight into our approach to multidimensional tumor profiles and guidance on interpreting their biological impact and diagnostic and therapeutic implications, we present case studies from the NCT/DKFZ molecular tumor board that illustrate our daily practice. This manual is intended to be useful for physicians, biologists, and bioinformaticians involved in the clinical interpretation of genome-wide molecular information | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Teleanu, Maria-Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Kreutzfeldt, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Heilig, Christoph E |e verfasserin |4 aut | |
| 700 | 1 | |a Hüllein, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Möhrmann, Lino |e verfasserin |4 aut | |
| 700 | 1 | |a Jahn, Arne |e verfasserin |4 aut | |
| 700 | 1 | |a Hanf, Dorothea |e verfasserin |4 aut | |
| 700 | 1 | |a Kerle, Irina A |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Hans Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hutter, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Uhrig, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Fröhlich, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, Olaf |e verfasserin |4 aut | |
| 700 | 1 | |a Hartig, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Brückmann, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Grund, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Dikow, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Lipka, Daniel B |e verfasserin |4 aut | |
| 700 | 1 | |a Renner, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatti, Irfan Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Apostolidis, Leonidas |e verfasserin |4 aut | |
| 700 | 1 | |a Schlenk, Richard F |e verfasserin |4 aut | |
| 700 | 1 | |a Schaaf, Christian P |e verfasserin |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e verfasserin |4 aut | |
| 700 | 1 | |a Schröck, Evelin |e verfasserin |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Heining, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Horak, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Glimm, Hanno |e verfasserin |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ precision oncology |d 2017 |g 7(2023), 1 vom: 26. Okt., Seite 109 |w (DE-627)NLM274781727 |x 2397-768X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:1 |g day:26 |g month:10 |g pages:109 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41698-023-00458-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 1 |b 26 |c 10 |h 109 | ||